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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is
oral zinc supplementation effective in reducing mortality rate in neonatal sepsis?”
STUDY DESIGN: Review of one randomized, double blind, controlled trial, one randomized
controlled trial and one randomized, double blind, placebo-controlled trial published in English
between 2013 and 2018.
DATA SOURCES: All three studies were gathered from peer-reviewed journals and found
using PubMed.
OUTCOMES MEASURED: Patient mortality rate, defined as during hospitalization for
treatment for Mehta el al. (Indian Pediatr. 2013;50(4):390-393. doi: S097475591200127 [pii]),
within 1 month of birth for Newton et al. (Indian J Pediatr. 2016;83(4);289-293.
doi:10.1007/s12098-015-1939-4 [doi]), and within 12 months of birth for Banupryia et al.
(Indian J Pediatr. 2018;85(1):5-9. doi: 10.1007/s12098-017-2444-8 [doi]).
RESULTS: The RCT performed by Mehta et al. (Indian Pediatr. 2013;50(4):390-393. doi:
S097475591200127 [pii]) showed no statistically significant reduction in the mortality rate
among the septic neonates supplemented with oral zinc when compared to the placebo group
(p=0.393). The mortality rate in the zinc group was 9.77% vs. 7.81% mortality rate in the
placebo group. Newton et al. (Indian J Pediatr. 2016;83(4);289-293. doi:10.1007/s12098-0151939-4 [doi]) similarly found no statistically significant reduction in mortality rate in those septic
infants treated with zinc supplementation when compared to the no zinc group (p=0.27) . The
mortality rate in the zinc group was 4.5% vs. 13.6% in the no zinc group. Conversely, Banupryia
et al. (Indian J Pediatr. 2018;85(1):5-9. doi: 10.1007/s12098-017-2444-8 [doi]) found a
statistically significant reduction in the mortality rate among septic neonates treated with oral
zinc supplementation when compared to neonates who did not receive zinc (p=0.04). The
mortality rate in the zinc group was 6.6% vs. 17.3% in the no zinc group.
CONCLUSIONS: The three RCTs evaluated in this review provided conflicting evidence on
whether or not oral zinc supplementation is effective in reducing mortality rate in neonatal
sepsis. Mehta et al. (Indian Pediatr. 2013;50(4):390-393. doi: S097475591200127 [pii]) and
Newton et al. (Indian J Pediatr. 2016;83(4);289-293. doi:10.1007/s12098-015-1939-4 [doi])
demonstrated no statistically significant reduction in mortality rate whereas Banupryia et al.
(Indian J Pediatr. 2018;85(1):5-9. doi: 10.1007/s12098-017-2444-8 [doi]) did acknowledge a
statistically significant reduction in mortality rate. Due to inconclusive results and limitations
noted in each study, further research is needed to better evaluate the effects of zinc
supplementation in reducing mortality rate in neonatal sepsis.
KEY WORDS: Zinc supplementation, neonatal sepsis
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INTRODUCTION
Neonatal sepsis is a systemic bacterial, viral, or fungal infection that affects infants
ranging from birth to three months of age. Due to their immature immune system, newborns are
at a higher risk for contracting infections. The infection can be passed from mother to baby or
can be contracted from outside sources after delivery.1 Once in contact with the causative agent,
the infection travels through the newborn’s blood stream causing a vast range of systemic
symptoms. A newborn with sepsis may present with a fever, reduced sucking for feeding,
diminished activity, lethargy, respiratory distress, hypoxia, seizures, vomiting and diarrhea.1 Due
to the debilitating nature of this disease healthcare personnel should have a low threshold for
treating a newborn when one presents with early septic signs and symptoms.
Sepsis is a major cause of morbidity and mortality among the newborn population.1 It is
estimated that the incidence rate of neonatal sepsis in the United States is 0.77-1 per 1,000 live
births.2 The mortality rate ranges from 3-40% depending on the organism and whether the
infection was early onset or late onset.3 Specific neonatal populations, including preterm and low
birth weight infants, have a higher incidence rate as well as mortality rate.2 Among the survivors
of the estimated 75,00 infants that contract sepsis each year, 47% will be hospitalized at least
once more in their lifetime due to complications stemming from the disease.4 Although an exact
overall annual healthcare cost for neonatal sepsis has not been identified, the annual cost for
neonatal sepsis caused by group B strep is estimated at $294 million.5 Medical advancements in
the field of neonatology continue, yet this deadly illness still prevails. Just as physician assistants
specialize in a variety of areas of medicine, by specializing in neonatology they can help treat the
youngest and most immunologically naïve patients.
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Several pathogens are known to cause neonatal sepsis, with the leading pathogen being
group B streptococcus. Other pathogens include, but are not limited to, Escherichia coli,
Streptococci virdans, Staphylococcus aureus, and Haemophilus influenzae.2 Whether
transmission of the bacteria occurs vertically or horizontally, the gold standard treatment is IV
antibiotics. Ampicillin with gentamicin is used for empiric treatment and vancomycin with an
aminoglycoside is used for hospital acquired pathogens.6 Once cultures are completed, antibiotic
therapy can be tailored to the specific pathogen. In addition to the antibiotics, supportive
treatment with IV fluids, oxygen and IV glucose is recommended.6 Upon identification of a
source, antibiotic treatment typically lasts 48 to 72 hours.3 Considering group B strep is the
leading cause of sepsis, medical efforts remain focused on prevention of vertical transmission
from mother to baby through prophylactic treatment during labor.3
Zinc is a mineral that is essential in maintaining the strength and function of the body’s
immune system.7 Deficiencies in this mineral impact the growth and function of T cells, B cells,
cytokines, and phagocytes.7 As mentioned earlier, newborns have an immature immune system
and struggle to fight off even the most common bacteria. Previous studies have confirmed the
benefits of zinc supplementation in increasing weight gain in low birth weight babies and
decreasing infection rate of certain diseases such as malaria and infectious diarrhea.7 Limited
studies have attempted to evaluate the effects of zinc supplementation in neonatal sepsis.7 This
paper analyzes three randomized controlled trials to evaluate the effectiveness of zinc
supplementation in reducing mortality rate of neonates with sepsis.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is oral zinc
supplementation effective in reducing mortality rate in neonatal sepsis?”
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METHODS
The key words used in the search of articles for this review included zinc
supplementation and neonatal sepsis. All three articles selected were published in English
between the 2013-2018. PubMed was used to research the articles which were selected based on
their qualification to answer to my clinical question in terms of a patient-oriented outcome.
Inclusion criteria consisted of studies that were RCTs published after 2008 and included the
neonatal population. Exclusion criteria consisted of studies published in 2008 or earlier and those
that were published in a foreign language. The statistics analyzed in this review included p-value
and NNT.
One randomized, double blind, controlled trial, one randomized controlled trial and one
randomized, double blind, placebo-controlled trial were utilized in this review. The focused
population for the studies of this review included neonates diagnosed with sepsis. In the study
performed by Mehta et al., the intervention group was given standard antibiotic therapy along
with oral zinc monohydrate supplementation.7 This group was compared to the control group
which was given standard antibiotic therapy with a placebo.7 In the studies performed by Newton
et al. and Banupriya et al. neonates receiving the intervention of standard antibiotic therapy with
oral zinc monohydrate supplementation were compared to the control group of those who
received the standard antibiotic therapy alone.8,9 The outcome measured in all three studies
included reduction in mortality rate.
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Table 1. Demographics & Characteristics of included studies
Study
Mehta7
(2013)

Newton8
(2016)

Type

#
Age
Pts
Double 614 Neonates
blind
>32
placebo
weeks
RCT

Inclusion
Criteria
Gestational
age >32
weeks,
parental
consent,
diagnosis of
“probable
sepsis” as
defined by
National
Neonatology
Forum of
India

Exclusion
W/D Interventions
Criteria
Parental
86
Placebo and
refusal to
standard
consent, pts <
antibiotic
32 weeks
therapy vs.
gestational
Zinc sulfate
age, 5 min
monohydrate
APGAR score
1mg/kg QD
<5, congenital
PO with
malformations,
standard
and
antibiotic
necrotizing
therapy until
enterocolitis
death or
discharge

RCT

Neonates
>32
weeks
and < 28
days old

Gestational
age >32
weeks, < 28
days old, on
enteral feeds
(>50%), at
least two
screening
tests
positive for
sepsis

150 Neonates
>32
weeks
and < 28
days old

Gestational
age >32
weeks, < 28
days old, on
enteral feeds
(>50%), at
least two
screening
tests
positive for
sepsis

Pts with
0
congenital
malformations,
necrotizing
enterocolitis,
have
undergone
surgery or
were treated
earlier for
sepsis, or who
had an
APGAR score
<6 at 5 min
Pts with
15
congenital
malformations,
necrotizing
enterocolitis,
have
undergone
surgery or
were treated
earlier for
sepsis, or who
had an
APGAR score
<6 at 5 min

Banupriya9 Double
(2018)
blind
RCT

88

Standard
antibiotic
therapy vs.
Zinc sulfate
monohydrate
3mg/kg BID
PO for 10
days with
standard
antibiotic
therapy

Standard
antibiotic
therapy vs.
Zinc sulfate
monohydrate
3mg/kg BID
PO for 10
days with
standard
antibiotic
therapy

4
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OUTCOMES MEASURED
Patient mortality rate was the outcome of focus for this EBM review. Each study defined
mortality rate within a different time frame. The study performed by Mehta et al. defined
mortality as death during hospitalization, Newton et al., defined mortality as death within one
month of birth and Banupriya et al. defined mortality as death within 12 months of birth.7,8,9
RESULTS
Mehta et al. conducted a double blind, randomized, placebo-controlled trial that analyzed
neonates with probable sepsis in a pediatric wing of a tertiary care hospital in Nepal from 2010
to 2011.7 The neonates included in this study were greater than 32 weeks gestational age, had
parental consent, and were given a diagnosis of “probable sepsis” as defined by the National
Neonatology Forum of India.7 Refer to Table 1 for the exclusion criteria. Of the neonates at the
hospital, 1540 were eligible for the study. After applying exclusion criteria, the total was
narrowed down to 700. These neonates were randomized evenly into the zinc group which
received 1mg/kg of zinc sulfate monohydrate by mouth daily with standard antibiotics and the
placebo group which received a placebo pill with standard antibiotic therapy.7 Both groups of
neonates were treated until they died or were discharged from the hospital. The neonates were
evaluated on a daily basis to assess their stability. A total of 86 babies were withdrawn from the
study leaving 614 to evaluated at the completion of the study. In the zinc group 9.77% (30/307
patients) died and in the placebo group 7.81% (24/307 patients) died (Table 2).7 No statistically
significant difference was observed as p= 0.393 and statistical significance was noted as p<0.05
(Table 2).7 The RBI was -0.24, the ABI was -0.019 and the NNT was -52 (Table 3). No safety
concerns or adverse side effects were discussed.
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In a NICU of a hospital in India, Newton et al. evaluated 88 neonates between 20132014.8 These babies were of greater than 32 weeks gestational age, less than 28 days old, on
enteral feeds and tested positive on at least two screening tests for sepsis.8 Refer to Table 1 for
the exclusion criteria. Prior to reviewing exclusion factors 215 neonates were eligible for the
study. After exclusion, 88 neonates were randomized into the intervention and control group.
The 44 infants in the intervention group were given zinc sulfate monohydrate 3mg/kg by mouth
twice daily for 10 days with the standard antibiotic therapy while the other 44 babies in the
control group were given standard antibiotic therapy alone.8 The neonates that had positive
screening tests received 7 days of antibiotics whereas those with positive cultures received 10
days of antibiotics.8 Zinc serum levels were taken in both groups prior to treatment and at the
conclusion of treatment on day 10. The neonates were evaluated each day while in the hospital
and were followed up with at one month of age.8 No drop outs were accounted for at the
conclusion of the study. Of those patients in the intervention group 4.5% (2/44 patients) died and
of those in the control group 13.6% (6/ 44 patients) died (Table 2).8 The p-value was 0.27 which
showed no statistically significant difference between the two groups (Table 2).8 However, the
NNT was 11 which showed a large positive treatment effect implying clinical significance. The
RBI was 0.67 and the ABI was 0.091 (Table 3). Additionally, no adverse effects were reported in
this study.
Banupriya et al. assessed septic neonates of a gestational age greater than 32 weeks and
less than 28 days old from 2013 to 2016 at the same hospital in India as a continuation of the
study conducted by Newton et al.9 The neonates included had to test positive on at least two
septic screening tests and had to be on enteral feeds.9 Refer to Table 1 for the exclusion criteria.
A total of 203 neonates were eligible for the study, but that number was narrowed down to 150
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due to exclusion factors. The patients were randomized and equally split into the intervention
zinc group and control no zinc group. In this double blinded study, the intervention group
received zinc sulfate monohydrate 3mg/kg by mouth twice daily for 10 days with standard
antibiotic therapy while the control group received only the standard antibiotic therapy.9 Once
again, zinc serum levels were taken from the neonates in both groups prior to the intervention
and upon completion of treatment on day 10. Throughout their hospital stay the babies were
monitored and were followed up at 12 months of age.9 At the completion of the study 6 drop outs
were accounted for in the control group and 9 were lost to follow up in the intervention group.9
A total of 17.3% (13/75 patients) neonates died in the no zinc group and 6.6% (5/75 patients)
died in the zinc group (Table 2).9 Between the two groups there was a statistically significant
difference in mortality rate (p<0.05) with p=0.04 (Table 2).9 The calculated RBI was 0.62, ABI
was 0.107 and NNT was 10 as recorded in Table 3. No adverse events or safety concerns for zinc
supplementation were noted.
Table 2. Patient Mortality and p-value by Study
Study

Zinc Group

No Zinc Group

P-value

Mehta et al.7

30 (9.77%)

24 (7.81%)

0.393

Newton et al.8

2 (4.5%)

6 (13.6%)

0.27

Banupriya et al.9

5 (6.6%)

13 (17.3%)

0.04
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Table 3. Calculations for Treatment from Mehta et al., Newton et al., and Banupriya et al.
Study

CER

EER

RBI

ABI

NNT

Mehta et al.7

0.078

0.097

-0.24

-0.019

-52

Newton et al.8

0.136

0.045

0.67

0.091

11

Banupriya et al.9

0.173

0.066

0.62

0.107

10

DISCUSSION
It is well known that zinc deficiency leads to impaired immune functioning. While
neonates in developing countries and those that are preterm are more at risk for being deficient,
all neonates are immunocompromised at birth with their immature immune system.9 The lack of
immunity in combination with the continuing struggle to fight sepsis despite tailored antibiotic
therapy leads to an increase of mortality in the world’s youngest population.9 While the goal of
this systemic EBM review was to evaluate the effects of oral zinc supplementation on reducing
mortality rate in neonatal sepsis, the three articles did not agree on a clear answer.
Mehta et al.’s RCT did not confirm statistical significance for zinc supplementation
reducing mortality rate in neonatal sepsis.7 The NNT was -52 and the zinc group had a higher
mortality rate than that of the placebo group.7 Similarly, Newton et al. did not establish statistical
significance supporting the benefit of zinc supplementation on reducing mortality rate in
neonatal sepsis.8 However, the NNT was 11, supporting a large treatment effect and clinical
significance.8 Lastly, Banupriya et al.’s RCT established statistical significance in that zinc
supplementation was effective in reducing mortality rate in neonatal sepsis.9 The NNT was 10,
supporting a large treatment effect and therefore clinical significance.9
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Each study came to a different conclusion in regard to the effectiveness of zinc in
reducing mortality rate in neonatal sepsis and each similarly noted their own limitations. Mehta
et al. acknowledged the limitations in that the study took place at a single location, the neonates
were not prescreened for an underlying zinc deficiency before they started the treatment, and that
the treatment length was not standardized.7 Newton et al. listed small sample size and marginal
zinc dose as limitations in their study.8 Lastly, Banupriya et al. specified the lack of a placebo
group and the short 10 day treatment of zinc as limitations within the study.9 Additionally, this
study was a continuation of a prior study, and thus, not all of the neonates were recruited at the
same time as the initial treatment group.9
Not only did the studies themselves pose limitations, but limitations arose when
searching for the studies. The studies by Newton et al. and Banupriya et al. were performed at
the same hospital in India, the latter being a continuation of the former.8,9 This systemic review
was limited to studies solely performed overseas. The two studies performed in India and the
other in Nepal restricted the generalizability of the results gathered. Lastly, the defined time
frame for mortality varied with each study, Mehta et al. defined mortality as death during
hospitalization, Newton et al. defined mortality within 1 month of birth and Banupriya et al.
defined mortality within 12 months of birth.7,8,9
CONCLUSION
Although cases can be made about the benefits zinc has on boosting the human immune
system, the three RCTs in this EBM review have provided conflicting evidence on whether or
not zinc supplementation is effective in reducing mortality rate in neonatal sepsis. Mehta et al.
and Newton et al. failed to establish statistical significance.7,8 In contrast, Banupriya et al. made
a statistically significant argument in favor of the benefits of zinc enhancing first line antibiotic
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treatment for neonatal sepsis.9 The variability in clinical and statistical significance implies that
further studies need to be performed to come to a definitive conclusion. Future studies are
needed to enhance generalizability and validity of the use of zinc in reducing mortality among
neonates with sepsis. These studies should account for infants that are breast vs. formula fed,
considering breastfeeding has been known to enhance immunity in infants and the studies should
have a universally defined time period for mortality. Furthermore, these studies should be
expanded to developed countries such as the United States and higher doses of zinc could be
studied to achieve a higher therapeutic level. Since mortality in the neonatal septic population
still exists even in the most medically advanced countries, zinc supplementation to aid in the
reduction of mortality rate should continue to be explored.
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